Metraipolis › archive › dc_d7a4e32283a9
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis — Europe PMC PMID:32109251
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32109251
- DOI
- 10.1371/journal.pntd.0008050
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T09:45:05.478Z
- SHA-256 of the archived text
acc0d3aaef3af36336d12643bacdff2b4a21a7f5acca9818f63f786ac5014fd9- Stable URL of this page
https://metraipolis.com/documento/dc_d7a4e32283a9
How to cite
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis — Europe PMC PMID:32109251 — Europe PMC (en), https://europepmc.org/article/MED/32109251 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_d7a4e32283a9 (Metraipolis archive dc_d7a4e32283a9, sha256 acc0d3aaef3af36336d12643bacdff2b4a21a7f5acca9818f63f786ac5014fd9)
BibTeX
@misc{dcd7a4e32283a9,
title = {CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis — Europe PMC PMID:32109251},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32109251},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_d7a4e32283a9; sha256 acc0d3aaef3af36336d12643bacdff2b4a21a7f5acca9818f63f786ac5014fd9},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32109251. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Cutaneous leishmaniasis (CL) affects the lives of 0.7-1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is lengthy and linked to significant toxicities; further, its efficacy is variable and resistant parasites are emerging. Shorter or lower dose antimonial treatment regimens, which would decrease the risk of adverse events and improve patient compliance, have shown reduced efficacy and further increase the risk emergence of antimonial-resistant strains. The progression of lesions in CL is partly determined by the immune response it elicits, and previous studies showed that administration of immunomodulatory type D CpG ODNs, magnifies the immune response to Leishmania and reduces lesion severity in nonhuman primates (NHP) challenged with Leishmania major or Leishmania amazonensis. Here we explored whether the addition of a single dose of immunomodulating CpG ODN D35 augments the efficacy of a short-course, low-dose pentavalent antimonial treatment regimen. Results show that macaques treated with D35 plus 5mg/kg sodium stibogluconate (SbV) for 10 days had smaller lesions and reduced time to re-epithelization after infection with Leishmania major. No toxicities were evident during the studies, even at doses of D35 10 times higher than those used in treatment. Critically, pentavalent antimonial treatment did not modify the ability of D35 to induce type I IFNs. The findings support the efficacy of D35 as adjuvant therapy for shorter, low dose pentavalent antimonial treatment. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS neglected tropical diseases, 2020 (prima pubblicazione 2020-02-28). Identificativi: PMID 32109251 · PMCID PMC7075640 · DOI 10.1371/journal.pntd.0008050. Pagina: https://europepmc.org/article/MED/32109251 — https://doi.org/10.1371/journal.pntd.0008050. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T09:40:42.927Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.